About the Study

Lyme Disease Vaccine

Lyme disease is an emerging tick-borne disease. It can cause a rash and flu-like symptoms. Untreated, Lyme disease can produce a wide range of symptoms depending on the stage of the infection. This can include fever, rash, facial paralysis, and arthritis with severe joint pain and swelling. Early signs and symptoms may include a small red bump followed by a bullseye rash. Because symptoms can be confused with other infections, early diagnosis is often difficult. Bloodwork suggesting infection may also be negative in the early phases of the illness.

Because Lyme infection can be so difficult to detect and treat, prevention with a vaccine would be a better approach to controlling the disease.  In the Northeast, especially New York State, Lyme disease has increased steadily over the past 25 years, according to the CDC. And is now the most commonly reported vector-borne illness in the United States.

Rochester Clinical Research is currently enrolling patients between the ages of 5 and 65 years old for a Lyme Disease Vaccine research study.  The purpose of the study will be to evaluate the study vaccines’ effectiveness in children, adolescents, and adults. This vaccine has been studied in adults prior to this study at RCR and has been well-tolerated.

The study will last approximately 12-13 months with 8 visits to our office. Compensation is available for time and travel for those who qualify. Study-related care is available to participants at no cost and health insurance is not required nor needed.

Qualifications

  • Between the ages of 5-17 years old
  • Cannot have had a tick bite in the past 4 weeks
  • Cannot have been diagnosed or treated for a chronic illness related to Lyme Disease within the last 3 months
  • Please note, other conditions may apply